EMEA-002066-PIP02-20
Key facts
Invented name |
Talzenna
|
Active substance |
talazoparib
|
Therapeutic area |
Oncology
|
Decision number |
P/130/2021
|
PIP number |
EMEA-002066-PIP02-20
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 (0)1304 646 607 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|